Nepstar three major risk.doc

 PAGE \* MERGEFORMAT 7 Nepstar three major risk November 9 last year, Sea King chain in the United States a successful New York Stock Exchange listing, financing, more than 2.4 billion yuan, from the rapid expansion of Sea King began its journey as a banner of China’s chain drugstores, Sea King is a great chain of pharmacies, the author of Neptune is the respected, and hope that China will see more such stores, so that supplies the retail trade to an early end to the melee, took to the true interests of the customer-oriented era. I stand in the perspective of a third party to observe the Sea King, Sea King hoped that this banner will fly high, it made the following suggestions and concerns for reference only. First, own-brand ‘has a product without a license’ risk Industry experts at a seminar, a Shanghai Fuxing Group’s executives commented on their own brands, said its own brand PB left the well-known brands (Brand) of B, its own brand that is a P (fart), the words of not without ridicule, but also reflects the development of domestic own-brand chain stores the facts, that is blocking well-known brands, obviously this is the most efficient way to one of China’s pharmaceutical products to the chain before the homogenization of such a opportunities and results of the Sea King was an early development of own-brand chain stores, the author agreed with the development of its own brand, according to some developing own-brand retailers such as Watson and Shu Puma information and international practice and develop their own Brand is an inevitable trend, but the own-brand products they are also carried out as a brand marketing, advertising, and the overall operation. I believe that the development of own-brand should be noted that four issues, namely, choose a well-known quality assured manufacturers to OEM, good quality control; 2 PB is to control the number of 20%. Dongsheng Technologies AG, Guan Ping, vice president, that the ‘white label drugs accounted for 10%